CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cell Immunotherapy For Adult B Cell Malignancies

Cameron J. Turtle, MD, covers the background and rationale for CD19 CAR-T cell therapy, clinical responses and approaches to mitigate toxicity.

Related Presenters

Cameron Turtle, MD.

Cameron Turtle, MD

Biography Cameron Turtle, M.D., Ph.D., is a hematology oncologist at SCCA, a UW assistant professor of Oncology and Medicine and a research associate at Fred Hutchinson Cancer Research Center. Patients with hematologic malignancies are ...

View full profile

Related Videos